abstract |
The present invention relates to the novel 4-(furo [3 with protein tyrosine kinase inhibit activities, 2-c] pyridine-2-base)-1,4-dihydrogen pyridine derivative, relate to its preparation method, and the purposes of the patient's condition relating to its disease being used for the treatment of c-Met mediation or c-Met mediation especially cancer and other proliferative disorders. |